These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 20504100)

  • 1. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
    Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
    Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
    Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
    Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.
    Katsikis I; Karkanaki A; Misichronis G; Delkos D; Kandaraki EA; Panidis D
    Eur J Obstet Gynecol Reprod Biol; 2011 Jun; 156(2):181-5. PubMed ID: 21353371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
    Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
    Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
    Barber TM; Wass JA; McCarthy MI; Franks S
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
    Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
    Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperprolactinaemia in polycystic ovary syndrome.
    Lunde O
    Ann Chir Gynaecol; 1981; 70(4):197-201. PubMed ID: 6797343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome.
    Cho LW; Jayagopal V; Kilpatrick ES; Holding S; Atkin SL
    Ann Clin Biochem; 2006 May; 43(Pt 3):217-9. PubMed ID: 16704758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose intolerance in Japanese patients with polycystic ovary syndrome.
    Kurioka H; Takahashi K; Miyazaki K
    Arch Gynecol Obstet; 2007 Mar; 275(3):169-73. PubMed ID: 16972071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia.
    Banaszewska B; Spaczyński RZ; Pelesz M; Pawelczyk L
    Rocz Akad Med Bialymst; 2003; 48():131-4. PubMed ID: 14737959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Exploration of the classification of polycystic ovarian syndrome].
    Lin JF; Li X; Zhu MW
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
    Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
    Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.